biotech.today

Details

  • ●Modalities: small molecules
  • ●Therapeutic areas: oncology
  • ●Key targets: HER2, BRCA
  • ●Indications: Undisclosed
  • ●Funding: $160M

Partners & investors

  • Catalio· Investor
  • NVIDIA· Investor
  • Section 32· Investor

Key considerations

  • ●AI tools in use: Enchant (generative), Insight (active learning)
  • ●$160M Series B (2024)
  • ●Backed by Catalio, Nvidia, Section 32
  • ●IAM-H1 entered clinic 2024

Pipeline

  • Phase 11
Get live updates on Iambic Therapeutics’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

Key people

Tom Miller

Co-Founder & CEO

computational-chemistry
Visit website →LinkedIn →